Seqirus USA Inc.

Seqirus USA Inc., a foreign-owned biotechnology manufacturer headquartered in Summit, New Jersey, supplies seasonal influenza vaccines to federal agencies as a prime contractor across full-and-open competitive procurements, with no set-aside posture. The vendor competes across civilian and defense health systems without SBA designations, drawing revenue from high-volume, low-margin delivery orders placed against established indefinite delivery contracts rather than from direct prime awards.

Seqirus manufactures and distributes quadrivalent flu vaccines, multi-dose vials, pre-filled syringes, and specialized high-dose formulations for pediatric, adult, and elderly populations. Recent concrete work includes a $30.9 million single-award IDC from the VA National Acquisition Center for 2026-2027 flu vaccines (awarded March 15, 2026), with task orders flowing from individual Veterans Integrated Service Networks for medical center orders ranging $14,000 to $187,000; a $168.1 million multiple-award pediatric flu vaccine IDC from the CDC (awarded December 31, 2025); a $82.7 million multiple-award adult flu vaccine IDC from the CDC (awarded December 31, 2025); and hundreds of small-dollar delivery orders from the Bureau of Prisons for correctional facility immunization, typically $500–$7,000 per order. Manufacturing and distribution occur at facilities in Summit, New Jersey; Swiftwater, Pennsylvania; and King of Prussia, Pennsylvania.

Customer concentration is extreme and driven by two customer classes. The CDC accounts for 55% of combined potential value across just 26 awards, anchored by the two 2025-2026 pediatric and adult flu vaccine contracts totaling $493.3 million in ceiling value. The Defense Logistics Agency Medical Supply Chain places 114 awards (25% of the top-five customer set by count) worth $563.3 million, predominantly for DOD troop readiness vaccine procurement. The Department of Veterans Affairs Veterans Health Administration distributes ordering across 149 facilities in Veterans Integrated Service Network 21, 73 in VISN 20, 71 in VISN 6, and 70 in VISN 5—resulting in high award count but low individual order value. The top five customers by potential value account for 55% of the combined $7.27 billion portfolio; the top five by award count account for just 25%.

Seqirus places work under multiple single-award and multiple-award IDCs. Major vehicles include the VA National Acquisition Center 2026-2027 IDC ($30.9 million, 191 task orders against predecessor vehicles); the CDC pediatric vaccine IDCs (combined $410.6 million–$318 million across award cycles); the CDC adult vaccine IDCs (combined $245.6 million–$215.7 million); Defense Logistics Agency Medical Supply Chain single-award IDCs for egg-free and standard formulations (ranging $2.26 million–$36.1 million per cycle); and a Federal Supply Schedule contract with VA VISN 12 under Pharmaceuticals and Drugs (FSS-61-IB, $2.56 million ceiling through August 2029). The vendor does not subcontract; 100% of awards are prime.

Activity has grown from 154 awards in 2022 to 105 in 2025 and 51 year-to-date in 2026, but most growth reflects ordering cadence against standing IDCs rather than new vehicle wins. Only five awards face completion within the next twenty-four months with combined potential value of $500 thousand—a negligible recompete cliff. This reflects Seqirus's position as a sole or dominant supplier of specialized vaccine products; CDC and VA awards are long-cycle vehicles issued annually or multi-year, generating recurring task orders rather than discrete contract competitions. The vendor's federal presence since 2008, established manufacturing capacity, FDA approval for multiple vaccine formulations, and specialized manufacturing scale create competitive barriers that limit recompete exposure.

Seqirus operates as a full-and-open competitor across all work, holding no 8(a), HUBZone, SDVOSB, WOSB, or small business certifications. Foreign ownership and the specialized, proprietary nature of vaccine manufacturing—coupled with biologics licensing and manufacturing compliance requirements—mean the vendor does not pursue set-aside vehicles. The vendor's $7.27 billion combined potential value and $779.3 million obligated across 1,918 awards over eighteen years positions it as the federal government's primary seasonal influenza vaccine supplier, with customer concentration dominated by public health agencies (CDC, VA, IHS) and defense medical supply (DLA). The customer and vehicle footprint is stable and recurring rather than competitive; Seqirus renews major CDC and VA IDCs on annual cycles, issues flow through task orders to downstream facilities, and the vendor faces limited pipeline disruption risk absent changes in vaccine formulation requirements or entry by competing manufacturers.